THOMAS WHEELER to DNA, Neoplasm
This is a "connection" page, showing publications THOMAS WHEELER has written about DNA, Neoplasm.
Connection Strength
0.340
-
DNA ploidy measurements in prostate cancer: differences between image analysis and flow cytometry and clinical implications. Prostate. 1994 Oct; 25(4):189-98.
Score: 0.105
-
A cancer DNA phenotype in healthy prostates, conserved in tumors and adjacent normal cells, implies a relationship to carcinogenesis. Proc Natl Acad Sci U S A. 2005 Dec 27; 102(52):19093-6.
Score: 0.057
-
Metastatic cancer DNA phenotype identified in normal tissues surrounding metastasizing prostate carcinomas. Proc Natl Acad Sci U S A. 2004 Aug 03; 101(31):11428-31.
Score: 0.052
-
Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol. 1994 May; 151(5):1301-7.
Score: 0.025
-
Comparison of the pathologic features and DNA ploidy value of prostate cancers detectable by sonography and by palpation. Prostate. 1993; 23(4):271-81.
Score: 0.023
-
DNA ploidy by image analysis of individual foci of prostate cancer: a preliminary report. Cancer Res. 1991 Aug 01; 51(15):4084-9.
Score: 0.021
-
Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 2004 Mar 15; 10(6):1992-9.
Score: 0.013
-
Age-related radical-induced DNA damage is linked to prostate cancer. Cancer Res. 2001 Aug 15; 61(16):6025-8.
Score: 0.011
-
Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000 Nov 01; 56(5):735-40.
Score: 0.010
-
Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998 Aug; 4(8):1873-80.
Score: 0.009
-
Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res. 1997 Aug; 3(8):1389-97.
Score: 0.008
-
The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J Cell Biochem Suppl. 1994; 19:283-9.
Score: 0.006